Medpace (MEDP) Margin Slippage Challenges Bullish Narratives Despite Solid Q4 EPS

Simply Wall St.04-24 10:19

Medpace Holdings (MEDP) has followed up its recent run of strong results with Q4 2025 revenue of US$708.5 million and basic EPS of US$4.78, backing that up with trailing 12 month revenue of about US$...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629895777?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-04-24 10:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629895777","market":"us","top_or_hot":-1,"title":"Medpace (MEDP) Margin Slippage Challenges Bullish Narratives Despite Solid Q4 EPS","media":"Simply Wall St.","content":"<div>\n<p>Medpace Holdings (MEDP) has followed up its recent run of strong results with Q4 2025 revenue of US$708.5 million and basic EPS of US$4.78, backing that up with trailing 12 month revenue of about US$...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/medpace-medp-margin-slippage-challenges-bullish-narratives-d\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medpace (MEDP) Margin Slippage Challenges Bullish Narratives Despite Solid Q4 EPS</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedpace (MEDP) Margin Slippage Challenges Bullish Narratives Despite Solid Q4 EPS\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-24 10:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/medpace-medp-margin-slippage-challenges-bullish-narratives-d><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Medpace Holdings (MEDP) has followed up its recent run of strong results with Q4 2025 revenue of US$708.5 million and basic EPS of US$4.78, backing that up with trailing 12 month revenue of about US$...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/medpace-medp-margin-slippage-challenges-bullish-narratives-d\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/medpace-medp-margin-slippage-challenges-bullish-narratives-d","article_id":"2629895777","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/medpace-medp-margin-slippage-challenges-bullish-narratives-d","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2629895777","pubTimestamp":1776997184,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Medpace Holdings (MEDP) has followed up its recent run of strong results with Q4 2025 revenue of US$708.5 million and basic EPS of US$4.78, backing that up with trailing 12 month revenue of about US$2.5 billion and EPS of US$15.64. Over recent quarters the company has seen revenue move from US$533.3 million in Q3 2024 to US$708.5 million in Q4 2025, while quarterly basic EPS has ranged from US$3.11 to US$4.78 across the same stretch. With trailing net profit margins at 17.8% versus 19.2% the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BLSG":"2倍做多BLSH ETF-Leverage Shares","MEDP":"Medpace Holdings Inc.","BK4588":"碎股","BK4112":"金融交易所和数据","BLSX":"Tradr 2X Long BLSH Daily ETF","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC"},"translate_title":"尽管第四季度每股收益稳健，但Medpace(MEDP)利润率下滑挑战了看涨叙事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLSG":0.6,"BLSX":0.6,"MEDP":1.98},"content_text":"Medpace Holdings (MEDP) has followed up its recent run of strong results with Q4 2025 revenue of US$708.5 million and basic EPS of US$4.78, backing that up with trailing 12 month revenue of about US$2.5 billion and EPS of US$15.64. Over recent quarters the company has seen revenue move from US$533.3 million in Q3 2024 to US$708.5 million in Q4 2025, while quarterly basic EPS has ranged from US$3.11 to US$4.78 across the same stretch. With trailing net profit margins at 17.8% versus 19.2% the prior year, the latest numbers point to solid profitability but with some pressure showing at the margin line. See our full analysis for Medpace Holdings. With the headline figures on the table, the next step is to set these results against the main narratives around Medpace to see which views the numbers support and which they push back on. See what the community is saying about Medpace Holdings NasdaqGS:MEDP Earnings & Revenue History as at Apr 2026 AdvertisementTTM earnings up 11.6% with steadier quarterly run rate  Over the last 12 months, earnings grew 11.6% while total revenue across that period was about US$2.5b, and quarterly net income in 2025 moved between US$90.3 million and US$135.1 million as EPS ranged from US$3.16 to US$4.78. Bulls point to this combination of double digit trailing earnings growth and relatively consistent quarterly EPS as support for the view that backlog conversion and operational execution can keep revenue and earnings growing strongly, even though the bullish narrative assumes profit margins could move from 18.7% to 16.2% over time.\n     What stands out for the bullish camp is that trailing net profit of US$451.1 million on US$2.53b of revenue lines up with their argument that current earnings power is already solid, even before any further backlog benefits show up. At the same time, the recent 11.6% earnings growth rate is lower than the 22.2% five year pace, which means bulls are leaning on execution and industry demand to offset that slower trend the numbers are already showing.    Supporters who think Medpace can keep converting its backlog efficiently may want to see how that full bullish case fits with these numbers 🐂 Medpace Holdings Bull Case Margins slip to 17.8% as mix shifts, feeding the cautious view  Trailing net profit margin sits at 17.8% compared with 19.2% the prior year, and quarterly net income across 2025 ranged from US$90.3 million to US$135.1 million even as quarterly revenue moved from US$558.6 million to US$708.5 million. Bears argue that this margin profile, alongside a heavy tilt toward faster burning studies and pass through revenue, supports their concern that current growth leans on factors that may not last, especially with backlog reportedly down about 1.8% year over year in the narrative.\n     The step down from 19.2% to 17.8% margin fits with the bearish worry that higher reimbursable costs and rising operating expenses can pressure profitability if project mix changes or hiring accelerates. At the same time, earnings still grew 11.6% over the year, which means the bearish thesis hinges more on what happens if growth slows than on any collapse in the trailing figures investors can see today.    If you are weighing those margin pressures against the growth profile, it helps to see how skeptics build their full argument 🐻 Medpace Holdings Bear Case P/E at 24.9x with DCF fair value well above market price  Medpace trades on a P/E of 24.9x compared with a peer average of 52.3x and industry 35.2x, and the DCF fair value of about US$604.00 sits well above the current share price of US$393.42. Consensus narrative highlights that, even with forecast earnings growth of about 9.5% a year and margin assumptions rising from 17.8% to 18.6%, the stock sits below an analyst price target reference of US$489.25 and below the DCF fair value, which some investors may see as a gap between the current multiple and the growth and profitability profile outlined in the forecasts.\n     The spread between the US$393.42 share price and the US$603.99 DCF fair value figure is large enough that valuation is likely to matter just as much as the modest slowdown from the 22.2% five year earnings growth rate to 11.6% last year. Because earnings growth forecasts at 9.46% a year sit below the 15.9% forecast for the broader US market, any case for rerating from a 24.9x P/E toward peer or industry levels has to be weighed directly against that slower growth profile.    Next Steps To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Medpace Holdings on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves. With all that in mind, how do you feel about the balance of risks and rewards here, and are you comfortable with your own read of the story so far? If you want to move quickly from headlines to specifics, start by looking at the 3 key rewards Explore Alternatives Medpace's slower 11.6% trailing earnings growth, alongside a margin step down from 19.2% to 17.8%, raises questions about how resilient its profitability really is. If you are concerned that moderating earnings momentum and tighter margins could limit upside here, it is worth comparing this profile with 55 high quality undervalued stocks.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629895777","isCrawlerRequest":true}